Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma-Reference-Cited by-同舟云学术

Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma

Published:2022-09-01 Issue:13 Volume:63 Page:3052-3062
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Oluwole Olalekan O.¹^ORCID,Chen Jenny M.H²,Chan Keith²,Patel Anik R.³,Jansen Jeroen P.⁴,Keeping Sam²^ORCID,Zheng Yan³,Snider Julia T.³^ORCID,Locke Frederick L.⁵^ORCID

Affiliation:

1. Vanderbilt‐Ingram Cancer Center, Nashville, TN, USA

2. PRECISIONheor, Vancouver, BC, Canada

3. Kite, A Gilead Company, Santa Monica, CA, USA

4. PRECISIONheor, Oakland, CA, USA

5. Moffitt Cancer Center, Tampa, FL, USA

Funder

Kite, A Gilead Company

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2113526

Reference32 articles.

1. Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma

2. Epidemiology of hematological malignancies

3. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study

4. Guidelines for the management of diffuse large B-cell lymphoma

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies;Expert Review of Anticancer Therapy;2024-04-24

2. Cost–effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan;Future Oncology;2024-04-10

3. Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma;Transplantation and Cellular Therapy;2023-07

4. Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications;Current Oncology;2023-05-15

5. How I approach optimization of patients at risk of cardiac and pulmonary complication after CAR-T cell therapy;Blood;2023-02-24